Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 6, 2008, Pages 1369-1375

  Oliveira, M S ^a   Prado, G V B ^a   Costa, S F ^a   Grinbaum, R S ^b   Levin, A S ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b HOSPITAL DO SERVIDOR PÚBLICO ESTADUAL DE SÃO PAULO   (Brazil)

Author keywords

Antibiotics; Colistin; Drug resistance

Indexed keywords

CARBAPENEM; COLISTIN; POLYMYXIN; POLYMYXIN B; SULTAMICILLIN; VANCOMYCIN;

ACINETOBACTER; ADOLESCENT; ADULT; AGE; AGED; ANTIBIOTIC RESISTANCE; APACHE; ARTICLE; BACTERIUM ISOLATION; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; FEMALE; HOSPITAL INFECTION; HOSPITAL PATIENT; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORTALITY; NEPHROTOXICITY; NEUROTOXICITY; PROGNOSIS; SEPTIC SHOCK; TEACHING HOSPITAL; THERAPY DELAY; TREATMENT RESPONSE;

EID: 44449173990     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn128     Document Type: Article

References (31)

1. Van Looveren M, Goossens H, the ARPAC Steering Group. Antimicrobial resistance of Acinetobacter spp. in Europe. Clin Microbiol Infect 2004; 10: 684-704.
2. Falagas ME, Kasiakou SK, Nikita D et al. Secular trends of antimicrobial resistance of blood isolates in a newly founded Greek hospital. BMC 2006; 6: 9.
3. Guzmán-Blanco M, Casellas JM, Sader HS. Bacterial resistance to antimicrobial agents in Latin America. Infect Dis Clin North Am 2000; 14: 67-81.
4. Wood GC, Hanes SD, Croce MA et al. Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of Acinetobacter ventilator-associated pneumonia. Clin Infect Dis 2002; 34: 1425-30.
5. Jellison TK, Mckinnon PS, Rybak MJ. Epidemiology resistance outcomes at Acinetobacter baumannii bacteremia treated with imipenem-cilastatin or ampicillin-sulbactam. Pharmacotherapy 2001; 21: 142-8.
6. Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: A comparison with imipenem-susceptible VAP. Clin Infect Dis 2003; 36: 1111-8.
7. Reina R, Estenssoro E, Saenz G et al. Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: A prospective cohort study. Intensive Care Med 2005; 31: 1058-65.
8. Levin AS, Barone AA, Penco J et al. Intravenous colistin as therapy for nosocomial infection caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999; 28: 1008-11.
9. Michalopoulos AS, Tsiodras S, Rellos K et al. Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: The renaissance of an old antibiotic. Clin Microbiol Infect 2005; 11: 115-21.
10. Kasiakou SK, Michalopoulos A, Soteriades ES et al. Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit Care 2003; 7: R78-83.
11. Kasiakou SK, Michalopoulus A, Soteriades ES et al. Combination theraphy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Antimicrob Agents Chemother 2005; 49: 3136-46.
12. Berlana D, Llop JM, Fort E et al. Use of colistin in the treatment of multiple-drug-resistant Gram-negative infections. Am J Health Syst Pharm 2005; 62: 39-47.
13. Falagas ME, Bliziotis IA, Kasiakou SK et al. Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria. BMC Infect Dis 2005; 5: 24.
14. Corbella X, Ariza J, Ardanuy C et al. Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter baumannii. J Antimicrob Chemother 1998; 42: 793-802.
15. Levin AS, Levy CE, Manrique AE et al. Severe nosocomial infections with imipenem-resistant Acinetobacter baumannii treated with ampicillin/sulbactam. Int J Antimicrob Agents 2003; 21: 58-62.
16. Cisneros JM, Reyes MJ, Pachón J et al. Bacteremia due to Acinetobacter baumannii: Epidemiology, clinical finding, and prognostic features. Clin Infect Dis 1996; 22: 1026-32.
17. Evans ME, Feola DJ, Rapp RP. Polymyxin B sulfate and colistin: Old antibiotics for emerging multiresistant Gram-negative bacteria. Ann Pharmacother 1999; 33: 960-7.
18. Horton J, Pankey GA. Polymyxin B, colistin sodium colistimethate. Med Clin North Am 1982; 66: 135-42.
19. Urban C, Go E, Mariano N et al. Effect of sulbactam on infections caused by imipenem-resistant Acinetobacter calcoaceticus biotype anitratus. J Infect Dis 1993; 167: 448-51.
20. Garner JS, Jarvis WR, Emori TG et al. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988; 16: 128-40.
21. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically - Fourth Edition: Approved Standard M7-A4. NCCLS, Wayne, PA, USA, 1996.
22. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing: M100-S5. NCCLS, Wayne, PA, USA, 1996.
23. Gales AC, Jones RN, Sader HS. Global assessment of the antimicrobial activity of polymyxin B againts 54731 clinical isolates of Gram-negative bacilli: Report from the SENTRY antimicrobial surveillance programme (2001-04). Clin Microbiol Infect 2006; 12: 315-21.
24. Knaus WA, Draper EA, Wagner DP et al. APACHE II: A severity of disease classification system. Crit Care Med 1985; 13: 818-29.
25. Bellomo R, Ronco C, Kellum JA et al. Acute Dialysis Quality Initiative workaroup. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 4: R204-12.
26. Kollef MH, Sherman G, Ward S et al. Inadequate antimicrobial treatment of infections: A risk factor for hospital mortality among critically ill Patients. Chest 1999; 115: 462-74.
27. Ibrahim EH, Sherman G, Ward S et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcome in the ICU setting. Chest 2000; 118: 146-55.
28. Iregui M, Ward S, Sherman G et al. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002; 122: 262-8.
29. Choi JY, Park YS, Kim CO et al. Mortality risk factors of Acinetobacter baumannii bacteraemia. Intern Med J 2005; 35 599-603.
30. Chen HP, Chen TL, Lai CH et al. Predictors of mortality in Acinetobacter baumannii bacteremia. J Microbiol Immunol Infect 2005; 38: 127-36.
31. Falagas ME, Kasiakou SK. Toxicity of polymyxins: A systematic review of the evidence from old and recent studies. Crit Care 2006; 10 R27.